US20200188325A1 - Cosmetic and topical compositions comprising cannabigerol - Google Patents

Cosmetic and topical compositions comprising cannabigerol Download PDF

Info

Publication number
US20200188325A1
US20200188325A1 US16/784,086 US202016784086A US2020188325A1 US 20200188325 A1 US20200188325 A1 US 20200188325A1 US 202016784086 A US202016784086 A US 202016784086A US 2020188325 A1 US2020188325 A1 US 2020188325A1
Authority
US
United States
Prior art keywords
cream
oil
cbg
deodorant spray
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/784,086
Inventor
Lekhram Changoer
George ANASTASSOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ApiRx Pharmaceutical USA LLC
Original Assignee
ApiRx Pharmaceutical USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ApiRx Pharmaceutical USA LLC filed Critical ApiRx Pharmaceutical USA LLC
Priority to US16/784,086 priority Critical patent/US20200188325A1/en
Assigned to APIRX PHARMACEUTICAL USA, LLC reassignment APIRX PHARMACEUTICAL USA, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Axim Biotechnologies, Inc.
Publication of US20200188325A1 publication Critical patent/US20200188325A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • Topical cosmetics and dermatological compositions relate to topical cosmetics and dermatological compositions and the topical application of such compositions to the skin for the prevention and/or treatment of damage to the skin.
  • the topical compositions comprise cannabigerol, a non-psychoactive phytocannabinoid.
  • the topical composition is anti-aging day cream, anti-aging night cream, eye cream, hand and nail cream, lip balm, acne cream and tonic, face wash, shampoo and conditioner, body wash, deodorant, or anti-diaper rash cream.
  • the cannabis plant has many naturally occurring substances that are of great interest in the fields of science and medicine.
  • Isolated compounds from the cannabis plant include ⁇ 9 -tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not.
  • Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids that have been isolated from the cannabis plant. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.
  • THC The IUPAC nomenclature of THC is ( ⁇ )-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol.
  • CBD's IUPAC nomenclature is 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-1,3-diol).
  • CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol.
  • CBG has the IUPAC nomenclature of 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzene-1,3-diol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
  • CBG cannabigerol
  • CBG has been shown to relieve intraocular pressure, which may help in the treatment of glaucoma. It can also be used to treat inflammatory bowel disease. CBG also inhibits the uptake of ⁇ -aminobutyric acid (GABA) in the brain, which in turn helps decrease anxiety. Research on rats has shown that CBG has an anti-nausea and anti-emetic effect, although human testing has yet to be carried out. One study even suggests that CBG inhibits the growth of color cancer cells. Another study found that CBG could potentially be helpful to treat many central nervous system disorders such as epilepsy.
  • GABA ⁇ -aminobutyric acid
  • Cannabinoids can be isolated by extraction or cold pressing from cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis , and Cannabis indica . These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
  • Nabilone (racemic(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name Dronabinol (( ⁇ )-(6aR,10aR)-6,6,9-trimythel-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol)).
  • nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet®.
  • Cosmetics are body-care substances used to enhance the human body's appearance or odor. Cosmetics are used to cleanse, beautify, promote attractiveness, and alter appearance without affecting the body's structure or function.
  • cosmetics applied to the skin (face and body), cosmetics applied to the lips, cleansing cosmetics (soap, shampoo, and conditioner), cosmetics applied to change odor (perfume, body mist, deodorant), and cosmetics applied to the eyes (mascara, eyebrow pencil).
  • Polyunsaturated fatty acids are essential to skin health. Metabolism of linoleic acid and alpha-linoleic acid is limited in skin. Topical and oral supplementations of essential fatty acids are effective means to supply these essential fatty acids to the skin. Some anti-aging cosmetic products do not include these important polyunsaturated fatty acids.
  • Essential fatty acids found in hemp oil act as moisturizers to trap moisture on the skin. Moreover, the fatty acids ratio in hemp oil closely matches the human skin composition and body, which is 3:1 ratio of omega-6 to omega-3 essential fatty acids. EFAs are proven to play a preventive role in skin aging and a healthy moisture balance for the skin.
  • Omega fatty acids are a group of unsaturated fatty acids considered to be important to physiological development in mammals.
  • omega-3 fatty acids are considered to be vital for normal metabolism.
  • These fatty acids receive their names based on the location of the first double bond from the tail end (omega end) of the carbon chain.
  • Omega-3 fatty acids are a group of three (3) fatty acids called ⁇ -linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Mammals have limited ability to synthesize omega-3 fatty acids. Given their importance in metabolism, mammals must consume omega-3 fatty acids to ensure normal metabolism.
  • ALA ⁇ -linolenic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Omega-6 fatty acids are a family of unsaturated fatty acids that have in common a carbon-carbon double bond in the n-6 position. Omega-6 fatty acids are considered to be important to a mammal's diet. The relative ratio of omega-6 to omega-3 fatty acids in Western diet is about 10:1 and up to 30:1. An excessive ratio of omega-6 to omega-3 fatty acids may interfere with omega-3 activity, storage, and conversion to eicosanoid precursors.
  • Terpenes refer to a large class of organic compounds produced by a variety of plants, particularly conifers. It is believed that they protect the plants that produce them by deterring herbivores and actually attracting predators and parasites of herbivores. Terpenes are the major ingredient in resin and form some of the major biosynthetic building blocks within nearly every living creature. Terpenes are the primary constituents of the essential oils of many plants. These essential oils are widely used as natural flavor additives for food, as fragrances in perfumes, and in medicine and alternative medicines in the form of aromatherapy. They are released by trees more actively in warmer weather and act as a natural form of cloud seeding, helping to regulate the temperature of the forest. Terpenes form the aroma and flavor in hops, which are highly desirable in some beers.
  • Terpin hydrate is a derivative of turpentine, and as an expectorant or humectant it is commonly used in the treatment of chronic or acute bronchitis and related conditions.
  • Cosmetics applied to the skin usually have anti-microbial, anti-oxidant, anti-aging, and wound healing properties.
  • Various substances are added to cosmetics to achieve these effects, and continuous efforts are still made to identify substances with these properties to be used in cosmetics.
  • the present invention relates to topical compositions comprising hemp oil or cannabis oil with naturally occurring cannabigerol at 3% to 24% by weight of the oil and cannabidiol at 1% to 10% by weight, and the oil comprises 0.2% to 10% by weight of the topical leave-on composition.
  • the concentrations of CBG hemp oil or cannabis oil are at 0.05% to 1.0% by weight of the topical rinse-off composition.
  • the topical composition is formulated to be anti-aging day cream, anti-aging night cream, eye cream, hand and nail cream, lip balm, acne cream and tonic, diaper rash cream, shampoo or conditioner, deodorant spray, face wash, or body wash.
  • the present invention also relates to methods to make the topical composition, and methods to use the topical composition for anti-aging, nourishing, cleansing, and acne treatment purposes.
  • CBD Cannabidiol
  • CBDV Cannabidivarin
  • CBG Cannabigerol
  • GABA ⁇ -aminobutyric acid
  • THC Tetrahydrocannabinol
  • cannabinoid used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs ( ⁇ 9 -tetrahydrocannabinol, ⁇ 8 -tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 3-(1,1-dimethylheptyl)-6,6a7,8,10,10a-hexahydro-1-1hydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9-ol, ( ⁇ )-(3 S,4 S)-7-hydroxy-delta-6-tetrahydrocannabinol-1,1-dimethylheptyl, (+)-(3 S,4S)-7-hydroxy-A-6-tetra
  • cannabidiol refers to cannabidiol and cannabidiol derivatives.
  • cannabidiol is obtained from industrial hemp extract with a trace amount of THC or from cannabis extract using high-CBD cannabis cultivars.
  • cannabigerol refers to cannabigerol and cannabigerol derivatives.
  • cannabigerol is industrial hemp extract with a trace amount of THC or from cannabis extract.
  • annabinol refers to cannabinol and cannabinol derivatives. As used in this application, cannabinol is obtained from cannabis extract or from industrial hemp extract.
  • Cannabinoids derived from natural sources usually come in oily form, known as cannabis oil, hashish oil, or hemp oil, depending on its origin, and is extract of the plant Cannabis sativa L. Cannabis sativa L.'s seed oil with naturally occurring cannabinoid content may also be used.
  • the oil has a liquid to paste-like profile at room temperature, and is hydrophobic.
  • Cannabis sativa L.'s seed oil or plant oil high in naturally occurring CBG may be used.
  • the topical dermatological compositions in these embodiments comprise Cannabis sativa L.'s oil with naturally occurring CBG.
  • CBG may be present in this oil at 3% to 24% by weight, even though higher weight percentage is contemplated.
  • Other naturally occurring cannabinoids may also be present, such as CBD at 3% to 10% by weight, and THC, CBC, CBN, or CBDV at lower weight percentage.
  • Cannabis oil or hemp oil with high naturally occurring CBG has anti-bacterial, anti-aging, neuro-protective, moisturizing, and anti-oxidant properties.
  • CBG oil may prevent and treat damage on skin, and may moisturize the skin to give a youthful appearance.
  • Anti-bacterial properties may help minimize the chance of acne development, as well as treating on-going acne on the dermis.
  • Topical dermal compositions used on the skin during daylight should have ultraviolet (UV) ray protection properties to protect the dermis from sun damage.
  • UV ultraviolet
  • CBG has neuro-protective properties as well as anti-oxidant properties, which may be useful is prevention of photodamage of the skin from UV rays exposures.
  • Terpenes in hemp oil or cannabis oil may provide anti-microbial properties, which may be desirable in cosmetics used for cleansing and/or in cosmetics applied to the skin. Terpenes may also add to the flavor of the cosmetics as a whole.
  • the topical composition may contain cannabis oil or hemp oil with naturally occurring CBG and CBD at about 0.2% to 10% by weight of the total composition, more preferably at about 2% to about 5% by weight of the total composition, for stay-on formulations.
  • Stay-on formulations are topical compositions applied to the skin and are not rinsed-off within a few minutes.
  • the topical composition may contain cannabis oil or hemp oil with naturally occurring CBG and CBD at about 0.05% to 1% by weight of the total composition.
  • Rinse-off formulations are topical compositions that may be rinsed off with water within a few minutes after application.
  • the topical composition may comprise other ingredients.
  • Anti-glycation agents may be added to this topical composition.
  • Anti-glycation agents are compounds for preventing and/or reducing the glycation of skin protein, such as a dermal protein like collagen.
  • the anti-glycation agent may inhibit the formation of advanced glycation end products.
  • Anti-glycation agents may be present in the topical composition at 0.1% to 5% by weight of the total composition.
  • anti-glycation agents may be extracts of Vaccinium angustifolium (blueberry), ergothioneine and its derivatives, hydroxystilbenes and their derivatives, benfotimaine, pyrisoxamine, G-rutin, pyridoxal phosphate, green tea extract, curcumin extract, Lupius albas seed oil, or Kigelia africana extract. Other anti-glycation agents may also be used.
  • Anti-inflammatory agents may be added to the topical composition to prevent and treat skin inflammation. Free radicals produced in aging skin may also induce inflammation of the skin and reduce skin immunity. Anti-inflammatory agents in topical compositions may work to reduce inflammation and increase skin health. Useful anti-inflammatory agents may be NSAIDS and COX-2 inhibitors, such as curcumin extract, evodia extract, Camellia sinesis extract, cocoa seed butter, citric acid, salicylic acid, tocopherol, loganin, palmatine, Vitis vinifera extract, among other anti-inflammatory ingredients. Anti-inflammatory agents may be present in the topical composition at 0.5% to 20% by weight.
  • ROS Reactive oxygen species
  • Living tissues have a control mechanism to keep ROS in balance.
  • Endogenous antioxidants defend the human body against ROS. When insufficient endogenous antioxidants are present, antioxidant supplements may work to inhibit the production of ROS by direct scavenging.
  • Antioxidants may also decrease the amount of oxidants in and around our cells, prevent ROS from reaching their biological targets, limit the propagation of oxidants, thwart oxidative stress, and ultimately prevent the aging process.
  • Anti-oxidants may be useful in cosmetic formulations to ease oxidative stress and prevent collagen degradation in the skin.
  • Suitable anti-oxidants for this topical formulation may be Vitis vinifera extract, tocopherol and tocopherol derivatives, certain lycopenes such as ⁇ -carotene, certain anthocyans (blueberry extract, basil grape extract), certain catechins (green tea extract, grape seed extract, litchi extract), certain quercetins (blueberry extract, grape seed extract, apple extract), certain genistein extract (gingoko biloba extract, soja extract), acetyl hexapeptide-3, Silybum marianum fruit extract, or silymarin (milk thistle).
  • Anti-oxidants may be incorporated into the topical formulation at 0.1% to 30% by weight of the total composition.
  • Anti-microbial ingredients protect against the growth of microorganisms in personal care products. Anti-microbial agents may also kill microorganisms present in the cosmetic product from the manufacturing process. Anti-microbial agents may be present in these embodiments to safeguard against microbial overgrowth, which may compromise the composition's quality as a whole.
  • Suitable anti-microbial agents may be imidazolidinyl urea, sodium chloride, or certain extracts having anti-microbial activities such as Matricaria chamomilla extract, Aloe vera extract, Calendula officinalis extract, Kigelia africana extract, Lavandulla officinallis essential oil, Melaleuca alternifolia essential oil, or Cinnamomum zeylanicum essential oil.
  • Anti-microbial agents may be present in the topical composition at 0.5% to 15% by weight of the total composition.
  • UV exposure may lead to multiple cellular damage by generating O 2 , H 2 O 2 , [—OH] and other reactive oxygen species.
  • the presence of oxidative groups may lead to skin aging, actinic damage, collagen and elastin degradation.
  • UVB rays (290-320 nm) are absorbed by epidermal chromophores such as melanin and urocanic acid and lead to direct molecular damage.
  • UVA rays 320-400 nm
  • UVA rays penetrate more deeply in the dermis, increase the production of ROS, and contribute to long-term actinic damage. UV ray damages may be mitigated with the use of certain agents that prevent and/or disrupt the destructive reactions caused by UV rays.
  • Suitable UV ray filter for this topical composition may be butylene glycol dicaprylyate or dicaprate, ethylhexyl methoxycinnamate, bis-ethylhexylloxyphenol methoxyphenyl triazine, camphor benzalkonium methosulfate, diethylhexyl butamido triazone, bisdisulizole disodium, drometrizole trisiloxane, ethylhexyl triazone, methyl anthranilate, 4-methylbenzylidene camphor, methylene bis-benzotriazolyl tetramethylbutyl phenol, octocrylene, butyl methoxydibenzoylmethane, phenylbenzimidazole sulfonic acid, polyacrylamidomethyl benzylidene camphor, or terephthalylidene dicamphor sulfonic acid.
  • UV ray filters may be added into the topical composition in embodiments used during the day, when skin exposure to sunlight is expected. UV ray filters may not be necessary for the topical compositions used during the night. UV ray filter agents may be present in the topical composition at 2% to 30% by weight of the total composition.
  • the topical composition may further comprise multiple skin conditioning agents.
  • Skin conditioning agents may work to increase moisture retention of the upper dermis layer, and thus give the skin an appearance of suppleness.
  • Certain skin conditioning agents may work to reduce flaky appearance and attract moisture from the environment, like a humectant.
  • Suitable skin conditioning agents may be butyrospermum parkii (shea butter), pentylene glycol, acetyl hexapeptide-3, lipobelle soyaglycone, xylitylglucoside, anhydroxyxylitol, xylitol, ethylhexylglycerin, squalene, Triticum vulgare germ oil unsaponifiables, ceramide-3, ethylhexyl stearate, biosaccharide gum-1, paraffinum liquidum, isopropyl palminate, glycerin stearate, D-panthenol, lactic acid, tocopherol and tocopherol derivatives, cetearyl alcohol, dicaprylyl carbonate, butylene alcohol, butylene glycol, and carnosine, butylene glycol cocoate, propylheptyl caprylate, glycine soja sterols (soybean
  • the topical composition may be a rash cream to treat diaper rash and other common rashes.
  • the topical composition may further comprise a soothing agent such as oxidized corn oil to provide a soothing feeling to the skin.
  • agents with keratolytic effect may be added into the topical composition. Hydrolyzed keratin and/or allantoin with keratolytic effect may be used in these embodiments. Keratolytic agents may be incorporated into this composition at 0.1% to 5% by weight of the total composition.
  • preservatives may be added into the topical composition to extend shelf life and prevent microbial growth.
  • Suitable preservatives may be pentylene glycol, phenoxyethanol, methyl and propylparaben, or ethylhexyl glycerin, or benzyl alcohol.
  • Other preservatives suitable for cosmetic use may also be used.
  • Preservatives may be present in the topical composition at 0.5% to 10% by weight of the total composition.
  • the topical formulation may comprise water, preferably de-ionized water, as the base, and bulking agent in this formulation. Water may comprise about 40% to about 80% by weight of the topical composition. However, in an embodiment wherein the topical composition is a lip balm, the composition comprises no water.
  • Viscosity controlling agents and emulsifiers may be necessary to bind water-phase ingredients and oil-phase ingredients.
  • Suitable emulsifiers for these embodiments may be hydrogenated lecithin, glycerin, sodium gluconate, acrylates, C10-30 alkyl acrylate crosspolymer, sodium carboxymethyl betaglucan, hydrogenated castor oil, polyglyceryl-3 methylglucose distearate, cetearyl alcohol, behenyl alcohol, butylene glycol, propylene glycol, xanthan gum, potassium cetyl phosphate, polyglyceryl-6 distearate jojoba esters, polyglyceryl-3 beewax, cetyl alcohol, PEG-800, laureth-7, C13-14 isoparrafin, polyisobutene, sodium carboxymethyl betaglucan, PEG-200 hydrogenated glyceryl palmate, cellulose gum, PEG-7 glyceryl cocoate, or aluminum starch
  • the topical composition may further comprise a foaming agent as needed.
  • Foaming agents may be quillaia saponaria extract or disodium EDTA (disodium ethylenediaminetetraacetic acid).
  • Fragrance agents in these embodiments may be added to increase the aesthetic appeal of the topical composition.
  • Fragrances may be propylparaben, hydrogenated castor oil, cinnamal, eugenol, coumarin, linalool, ⁇ -isomethyl ionone, hydroxyisohexyl 3-cyclohexene carboxaldehyde, butylphenyl methylpropional, or natural fragrance essential oils.
  • the topical composition according to the above embodiments may be formulated to be an anti-aging day cream, anti-aging night cream, hand and nail cream, acne treatment cream or tonic, anti-diaper rash cream, shampoo (regular and anti-dandruff), conditioner, face wash, and body wash.
  • the topical composition is a lip balm.
  • the topical composition may comprise, apart from CBG hemp oil or CBG cannabis oil at about 1% to 3% by weight of the topical composition, cosmetically suitable waxes, cosmetic oils or butter, flavor, and moisturizing agents.
  • CBG hemp oil or CBG cannabis oil as used in these embodiments may have about 3% to 24% CBG, and 1% to 10% CBD by weight, with other naturally occurring cannabinoids at lower weight percentage.
  • Suitable waxes for use in this embodiment may be bee wax, lanolin, candelilla, soy, or carnauba wax.
  • Other skin conditioning agents may be added to give the composition a softer profile.
  • Suitable skin conditioning agents may be cocoa butter, Ricinus communis (castor) seed oil, olive oil, coconut oil, and avocado oil. Other suitable skin conditioning agents may also be used.
  • Flavoring oils such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any suitable flavor, may be added into the topical composition according to this embodiment.
  • flavoring oils such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry
  • the topical composition may be a shampoo, conditioner, a face wash, or body wash
  • the topical composition may contain, apart from CBG hemp oil or CBG cannabis oil, other ingredients common in shampoo, conditioner, face wash, or body wash.
  • the concentrations of CBG hemp oil or CBG cannabis oil in these products may be at 0.05% to 1% by weight of the topical rinse-off composition.
  • Suitable surfactants, cleansing agents, additives, antimicrobials, and thickeners in these embodiments may be ammonium chloride, ammonium lauryl sulfate, sodium laureth sulfate, sodium lauryl sulfate, piroctone olamine, sodium lauroamphoacetate, polysorbate 20, polysorbate 80, PEG-150, citric acid, quaternium-15, polyquaternium-10, coco-glucoside, cocamide MEA, methylisothiazolinone, or di-PGG-2 myreth-10 adipate.
  • Piroctone olamine may be used as an antimicrobial agent in shampoo embodiments for anti-dandruff purposes.
  • the topical composition may be a conditioner.
  • the conditioner may comprise, in addition to CBD hemp oil or CBG cannabis oil, certain humectants; certain reconstructors such as hydrolyzed protein, glossers such as silicones; thermal protectors; certain lubricants such as fatty alcohols, panthenol, or dimethicone; certain sequestrants, such as sodium gluconate, potassium gluconate, or calcium disodium ethylene diamine tetra-acetate; antistatic agents; or preservatives.
  • the topical composition may be a deodorant spray.
  • the deodorant spray according to these embodiments may comprise CBG hemp oil or CBG cannabis oil at 0.1% to 1.5% by weight of the deodorant spray as a whole.
  • CBG hemp oil or CBG cannabis oil as used in these embodiments may have about 3% to 24% CBG, and 1% to 10% CBD by weight, with other naturally occurring cannabinoids at lower weight percentage.
  • the deodorant spray may further comprise alcohol, such as ethanol and isopropyl alcohol as the main carrier.
  • Suitable emulsifiers and humectants may be added, such as glycerin, polysorbate 20, methylcyclodextrin, or ethylhexyl glycerin. Other suitable emulsifiers may also be used. Fragrance in the form of natural essential oils may be added to give a pleasant scent.
  • Flavoring oils such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any suitable flavor, may be added into the deodorant spray as fragrance according to these embodiments.
  • ingredients may be obtained according to the embodiments above.
  • Water phase ingredients may be combined and mixed.
  • Oily phase ingredients may be combined and mixed with heat application at about 50° C. to about 70° C. to reduce viscosity and facilitate mixing.
  • Water phase and oil phase may be combined under continuous mixing and heating.
  • the water phase comprises of de-ionized water, bulking agents, cosmetic fillers, emulsifiers, preservatives, and anti-caking agents. Ingredients for the water phase may be combined and mixed. Water phase ingredients may be separated into different sequences as needed.
  • the oily phase may comprise hemp oil, tocopherol, lipobelle soyaglycone, fragrance, essential oils, and other oily ingredients. Ingredients for the oily phase may be combined and mixed while heated. Other ingredients may be added in sufficient quantities, such as sodium hydroxide for pH balancing purposes.
  • ingredients may be obtained according to the above embodiments.
  • combine skin conditioning oils and hemp oil with CBD and CBG then heat to about 35° C. to about 45° C.
  • the lip balm composition may be applied to lips.
  • ingredients may be obtained according to the description above.
  • a base comprising of water and alcohols may be pre-mixed in a container.
  • Emulsifiers and humectants may be mixed with CBG hemp oil or CBG cannabis oil; then added into the base. Fragrance may be added as needed to the composition.
  • Anti-aging creams according to embodiments may be applied at least once daily to human skin to reduce signs of aging, including sagging skin, discoloration, dryness, and crow's feet.
  • Hand and nail cream may be applied at least once daily to nourish and moisturize the skin.
  • Acne cream according to the present invention may be applied at least once daily to prevent and treat acne.
  • Lip balm according to these embodiments may be applied as needed to the lips to moisturize and preserve lips' health.
  • Shampoo, conditioner, face wash, and body wash may be applied to the hair or skin with water to wash, nourish, and moisturize the hair and the skin.
  • Shampoo, conditioner, face wash, and body wash may be applied daily, or as needed.
  • Deodorant spray may be applied to the skin twice daily or as needed.
  • Ethanol 72.50 De-ionized Water 14.00 Glycerin 6.00 Isopropyl Alcohol 3.00 Fragrance 3.00 Ethylhexylglycerin 1.00 Hemp oil (CBD/CBG) 0.50 Total 100.00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Gerontology & Geriatric Medicine (AREA)

Abstract

This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 15/044,322, filed Feb. 16, 2016, which claims the benefit of U.S. Provisional Application No. 62/116,905 filed Feb. 16, 2015, the entire content of which is hereby incorporated by reference in its entirety.
    • BACKGROUND OF THE INVENTION Field of the Invention
  • This invention relates to topical cosmetics and dermatological compositions and the topical application of such compositions to the skin for the prevention and/or treatment of damage to the skin. The topical compositions comprise cannabigerol, a non-psychoactive phytocannabinoid. The topical composition is anti-aging day cream, anti-aging night cream, eye cream, hand and nail cream, lip balm, acne cream and tonic, face wash, shampoo and conditioner, body wash, deodorant, or anti-diaper rash cream.
    • Description of the Related Technology
  • The cannabis plant has many naturally occurring substances that are of great interest in the fields of science and medicine. Isolated compounds from the cannabis plant include Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), cannabidivarin (CBDV), among other compounds. While THC has psychoactive effects, CBD, CBC, CBG, and CBDV do not. Isolated compounds from the cannabis plant are called cannabinoids. There are a total of eighty-five (85) cannabinoids that have been isolated from the cannabis plant. Cannabinoids have been investigated for possible treatment of seizures, nausea, vomiting, lack of appetite, pain, arthritis, inflammation, and other conditions.
  • The IUPAC nomenclature of THC is (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol. CBD's IUPAC nomenclature is 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-1,3-diol). CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol. CBG has the IUPAC nomenclature of 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzene-1,3-diol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
  • Because it is a relatively unknown cannabinoid, cannabigerol (CBG) remains understudied and its effects are only just starting to become clear. CBG is a non-psychoactive cannabinoid found in the cannabis plant. All cannabinoids in the early stage of the cannabis plant's life begins as CBG. CBG is found in higher concentrations in hemp plants as opposed to marijuana plants that are grown to have higher concentrations of tetrahydrocannabinol (THC). CBG has been found to act as a high affinity α2-adrenergic receptor agonist, a moderate affinity 5-HT1A receptor antagonist, and a low affinity CB1 receptor antagonist. It binds with the CB2 receptor, but it is currently unknown whether it acts as an agonist or antagonist.
  • CBG has been shown to relieve intraocular pressure, which may help in the treatment of glaucoma. It can also be used to treat inflammatory bowel disease. CBG also inhibits the uptake of γ-aminobutyric acid (GABA) in the brain, which in turn helps decrease anxiety. Research on rats has shown that CBG has an anti-nausea and anti-emetic effect, although human testing has yet to be carried out. One study even suggests that CBG inhibits the growth of color cancer cells. Another study found that CBG could potentially be helpful to treat many central nervous system disorders such as epilepsy.
  • Cannabinoids can be isolated by extraction or cold pressing from cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis, and Cannabis indica. These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
  • Nabilone (racemic(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name Dronabinol ((−)-(6aR,10aR)-6,6,9-trimythel-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol)). These synthetic cannabinoids are sold for food supplement purposes and are being investigated for medicinal purposes. The U.S. Food and Drug Administration approved nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet®.
  • Cosmetics are body-care substances used to enhance the human body's appearance or odor. Cosmetics are used to cleanse, beautify, promote attractiveness, and alter appearance without affecting the body's structure or function.
  • Various types of cosmetics exist. Generally, they are cosmetics applied to the skin (face and body), cosmetics applied to the lips, cleansing cosmetics (soap, shampoo, and conditioner), cosmetics applied to change odor (perfume, body mist, deodorant), and cosmetics applied to the eyes (mascara, eyebrow pencil).
  • Polyunsaturated fatty acids (omega-6 and omega-3) are essential to skin health. Metabolism of linoleic acid and alpha-linoleic acid is limited in skin. Topical and oral supplementations of essential fatty acids are effective means to supply these essential fatty acids to the skin. Some anti-aging cosmetic products do not include these important polyunsaturated fatty acids.
  • Essential fatty acids (EFAs) found in hemp oil act as moisturizers to trap moisture on the skin. Moreover, the fatty acids ratio in hemp oil closely matches the human skin composition and body, which is 3:1 ratio of omega-6 to omega-3 essential fatty acids. EFAs are proven to play a preventive role in skin aging and a healthy moisture balance for the skin.
  • Omega fatty acids are a group of unsaturated fatty acids considered to be important to physiological development in mammals. In particular, omega-3 fatty acids are considered to be vital for normal metabolism. These fatty acids receive their names based on the location of the first double bond from the tail end (omega end) of the carbon chain.
  • Omega-3 fatty acids are a group of three (3) fatty acids called α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Mammals have limited ability to synthesize omega-3 fatty acids. Given their importance in metabolism, mammals must consume omega-3 fatty acids to ensure normal metabolism.
  • Omega-6 fatty acids are a family of unsaturated fatty acids that have in common a carbon-carbon double bond in the n-6 position. Omega-6 fatty acids are considered to be important to a mammal's diet. The relative ratio of omega-6 to omega-3 fatty acids in Western diet is about 10:1 and up to 30:1. An excessive ratio of omega-6 to omega-3 fatty acids may interfere with omega-3 activity, storage, and conversion to eicosanoid precursors.
  • Terpenes refer to a large class of organic compounds produced by a variety of plants, particularly conifers. It is believed that they protect the plants that produce them by deterring herbivores and actually attracting predators and parasites of herbivores. Terpenes are the major ingredient in resin and form some of the major biosynthetic building blocks within nearly every living creature. Terpenes are the primary constituents of the essential oils of many plants. These essential oils are widely used as natural flavor additives for food, as fragrances in perfumes, and in medicine and alternative medicines in the form of aromatherapy. They are released by trees more actively in warmer weather and act as a natural form of cloud seeding, helping to regulate the temperature of the forest. Terpenes form the aroma and flavor in hops, which are highly desirable in some beers.
  • A range of terpenes have been identified as high-value chemicals in food, cosmetic, pharmaceutical, and biotechnology industries. They are generally difficult to produce synthetically, due to their complex structures. Research has shown that many terpenes possess qualities that make them ideal active ingredients as part of natural agricultural pesticides. Terpin hydrate is a derivative of turpentine, and as an expectorant or humectant it is commonly used in the treatment of chronic or acute bronchitis and related conditions.
  • Cosmetics applied to the skin, whether stay-on or rinse-off, usually have anti-microbial, anti-oxidant, anti-aging, and wound healing properties. Various substances are added to cosmetics to achieve these effects, and continuous efforts are still made to identify substances with these properties to be used in cosmetics.
    • SUMMARY
  • The present invention relates to topical compositions comprising hemp oil or cannabis oil with naturally occurring cannabigerol at 3% to 24% by weight of the oil and cannabidiol at 1% to 10% by weight, and the oil comprises 0.2% to 10% by weight of the topical leave-on composition. In the rinse off formulations, the concentrations of CBG hemp oil or cannabis oil are at 0.05% to 1.0% by weight of the topical rinse-off composition. The topical composition is formulated to be anti-aging day cream, anti-aging night cream, eye cream, hand and nail cream, lip balm, acne cream and tonic, diaper rash cream, shampoo or conditioner, deodorant spray, face wash, or body wash. The present invention also relates to methods to make the topical composition, and methods to use the topical composition for anti-aging, nourishing, cleansing, and acne treatment purposes.
    • Abbreviations
  • CBC: Cannabichromene
  • CBD: Cannabidiol
  • CBDV: Cannabidivarin
  • CBG: Cannabigerol
  • CBN: Cannabinol
  • GABA: γ-aminobutyric acid
  • INCI: International Cosmetic Ingredient Nomenclature Committee
  • IUPAC: International Union of Pure and Applied Chemistry
  • SPF: Sun Protection Factor
  • THC: Tetrahydrocannabinol
  • UV: Ultraviolet
    • DETAILED DESCRIPTION OF CERTAIN INVENTIVE EMBODIMENTS
  • This present invention is capable of being embodied in various forms. The description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the attached claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
  • As used herein, the verb “to comprise” in this description, claims, and other conjugations are used in their non-limiting sense to mean those items following the word are included, but items not specifically mentioned are not excluded.
  • Reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one.” Additionally, the words “a” and “an” when used in the present document in concert with the words “comprising” or “containing” denote “one or more.”
  • The word “cannabinoid” used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs (Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, 3-(1,1-dimethylheptyl)-6,6a7,8,10,10a-hexahydro-1-1hydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9-ol, (−)-(3 S,4 S)-7-hydroxy-delta-6-tetrahydrocannabinol-1,1-dimethylheptyl, (+)-(3 S,4S)-7-hydroxy-A-6-tetrahydrocannabinol, and Δ8-tetrahydrocannabinol-11-oic acid); certain piperidine analogs (e.g., (−)-(6S,6aR,9R,10aR)-5,6,6a,7,8,9,10,10a-octahydro-6-methyl-1-3-[(R)-1-methyl-4-phenylbutoxy]-1,9-phenanthridinediol 1-acetate)); certain aminoalkylindole analogs (e.g., (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylm-ethyl)-pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthelenyl-methanone); certain open pyran-ring analogs (e.g., 2-[3-methyl-6-(1-methylethenyl-2-cyclohexen-1-yl]-5-pentyl-1,3-benzendi-ol, and 4-(1,1-dimethylheptyl)-2,3 ‘-dihydroxy-6’-α-(3-hydroxypropyl)-1′,-2′,3′,4′,5′,6′-hexahydrobiphenyl), their salts, solvates, metabolites, and metabolic precursors.
  • The word “cannabidiol” refers to cannabidiol and cannabidiol derivatives. As used in this application, cannabidiol is obtained from industrial hemp extract with a trace amount of THC or from cannabis extract using high-CBD cannabis cultivars.
  • The word “cannabigerol” refers to cannabigerol and cannabigerol derivatives. As used in this application, cannabigerol is industrial hemp extract with a trace amount of THC or from cannabis extract.
  • The word “cannabinol” refers to cannabinol and cannabinol derivatives. As used in this application, cannabinol is obtained from cannabis extract or from industrial hemp extract.
  • Cannabinoids derived from natural sources usually come in oily form, known as cannabis oil, hashish oil, or hemp oil, depending on its origin, and is extract of the plant Cannabis sativa L. Cannabis sativa L.'s seed oil with naturally occurring cannabinoid content may also be used. The oil has a liquid to paste-like profile at room temperature, and is hydrophobic. In these embodiments, Cannabis sativa L.'s seed oil or plant oil high in naturally occurring CBG may be used.
  • The topical dermatological compositions in these embodiments comprise Cannabis sativa L.'s oil with naturally occurring CBG. CBG may be present in this oil at 3% to 24% by weight, even though higher weight percentage is contemplated. Other naturally occurring cannabinoids may also be present, such as CBD at 3% to 10% by weight, and THC, CBC, CBN, or CBDV at lower weight percentage.
  • Cannabis oil or hemp oil with high naturally occurring CBG has anti-bacterial, anti-aging, neuro-protective, moisturizing, and anti-oxidant properties. When used for dermal application, CBG oil may prevent and treat damage on skin, and may moisturize the skin to give a youthful appearance. Anti-bacterial properties may help minimize the chance of acne development, as well as treating on-going acne on the dermis.
  • Topical dermal compositions used on the skin during daylight should have ultraviolet (UV) ray protection properties to protect the dermis from sun damage. Depending on the strength of sunlight and geographic areas, the demand for UV ray protection may vary. CBG has neuro-protective properties as well as anti-oxidant properties, which may be useful is prevention of photodamage of the skin from UV rays exposures.
  • Terpenes in hemp oil or cannabis oil may provide anti-microbial properties, which may be desirable in cosmetics used for cleansing and/or in cosmetics applied to the skin. Terpenes may also add to the flavor of the cosmetics as a whole.
  • In embodiments, the topical composition may contain cannabis oil or hemp oil with naturally occurring CBG and CBD at about 0.2% to 10% by weight of the total composition, more preferably at about 2% to about 5% by weight of the total composition, for stay-on formulations. Stay-on formulations are topical compositions applied to the skin and are not rinsed-off within a few minutes.
  • For rinse-off formulation, the topical composition may contain cannabis oil or hemp oil with naturally occurring CBG and CBD at about 0.05% to 1% by weight of the total composition. Rinse-off formulations are topical compositions that may be rinsed off with water within a few minutes after application.
  • Depending on the specific formulation, the topical composition may comprise other ingredients. Anti-glycation agents may be added to this topical composition. Anti-glycation agents are compounds for preventing and/or reducing the glycation of skin protein, such as a dermal protein like collagen. The anti-glycation agent may inhibit the formation of advanced glycation end products. Anti-glycation agents may be present in the topical composition at 0.1% to 5% by weight of the total composition.
  • Examples of anti-glycation agents may be extracts of Vaccinium angustifolium (blueberry), ergothioneine and its derivatives, hydroxystilbenes and their derivatives, benfotimaine, pyrisoxamine, G-rutin, pyridoxal phosphate, green tea extract, curcumin extract, Lupius albas seed oil, or Kigelia africana extract. Other anti-glycation agents may also be used.
  • Anti-inflammatory agents may be added to the topical composition to prevent and treat skin inflammation. Free radicals produced in aging skin may also induce inflammation of the skin and reduce skin immunity. Anti-inflammatory agents in topical compositions may work to reduce inflammation and increase skin health. Useful anti-inflammatory agents may be NSAIDS and COX-2 inhibitors, such as curcumin extract, evodia extract, Camellia sinesis extract, cocoa seed butter, citric acid, salicylic acid, tocopherol, loganin, palmatine, Vitis vinifera extract, among other anti-inflammatory ingredients. Anti-inflammatory agents may be present in the topical composition at 0.5% to 20% by weight.
  • Reactive oxygen species (ROS) are either free radicals or non-radical with high oxidative properties. Living tissues have a control mechanism to keep ROS in balance. Endogenous antioxidants defend the human body against ROS. When insufficient endogenous antioxidants are present, antioxidant supplements may work to inhibit the production of ROS by direct scavenging. Antioxidants may also decrease the amount of oxidants in and around our cells, prevent ROS from reaching their biological targets, limit the propagation of oxidants, thwart oxidative stress, and ultimately prevent the aging process.
  • Anti-oxidants may be useful in cosmetic formulations to ease oxidative stress and prevent collagen degradation in the skin. Suitable anti-oxidants for this topical formulation may be Vitis vinifera extract, tocopherol and tocopherol derivatives, certain lycopenes such as β-carotene, certain anthocyans (blueberry extract, basil grape extract), certain catechins (green tea extract, grape seed extract, litchi extract), certain quercetins (blueberry extract, grape seed extract, apple extract), certain genistein extract (gingoko biloba extract, soja extract), acetyl hexapeptide-3, Silybum marianum fruit extract, or silymarin (milk thistle). Anti-oxidants may be incorporated into the topical formulation at 0.1% to 30% by weight of the total composition.
  • Anti-microbial ingredients protect against the growth of microorganisms in personal care products. Anti-microbial agents may also kill microorganisms present in the cosmetic product from the manufacturing process. Anti-microbial agents may be present in these embodiments to safeguard against microbial overgrowth, which may compromise the composition's quality as a whole.
  • Suitable anti-microbial agents may be imidazolidinyl urea, sodium chloride, or certain extracts having anti-microbial activities such as Matricaria chamomilla extract, Aloe vera extract, Calendula officinalis extract, Kigelia africana extract, Lavandulla officinallis essential oil, Melaleuca alternifolia essential oil, or Cinnamomum zeylanicum essential oil. Anti-microbial agents may be present in the topical composition at 0.5% to 15% by weight of the total composition.
  • UV exposure may lead to multiple cellular damage by generating O2, H2O2, [—OH] and other reactive oxygen species. The presence of oxidative groups may lead to skin aging, actinic damage, collagen and elastin degradation. UVB rays (290-320 nm) are absorbed by epidermal chromophores such as melanin and urocanic acid and lead to direct molecular damage. UVA rays (320-400 nm) penetrate more deeply in the dermis, increase the production of ROS, and contribute to long-term actinic damage. UV ray damages may be mitigated with the use of certain agents that prevent and/or disrupt the destructive reactions caused by UV rays.
  • Suitable UV ray filter for this topical composition may be butylene glycol dicaprylyate or dicaprate, ethylhexyl methoxycinnamate, bis-ethylhexylloxyphenol methoxyphenyl triazine, camphor benzalkonium methosulfate, diethylhexyl butamido triazone, bisdisulizole disodium, drometrizole trisiloxane, ethylhexyl triazone, methyl anthranilate, 4-methylbenzylidene camphor, methylene bis-benzotriazolyl tetramethylbutyl phenol, octocrylene, butyl methoxydibenzoylmethane, phenylbenzimidazole sulfonic acid, polyacrylamidomethyl benzylidene camphor, or terephthalylidene dicamphor sulfonic acid.
  • UV ray filters may be added into the topical composition in embodiments used during the day, when skin exposure to sunlight is expected. UV ray filters may not be necessary for the topical compositions used during the night. UV ray filter agents may be present in the topical composition at 2% to 30% by weight of the total composition.
  • The topical composition may further comprise multiple skin conditioning agents. Skin conditioning agents may work to increase moisture retention of the upper dermis layer, and thus give the skin an appearance of suppleness. Certain skin conditioning agents may work to reduce flaky appearance and attract moisture from the environment, like a humectant.
  • Suitable skin conditioning agents may be butyrospermum parkii (shea butter), pentylene glycol, acetyl hexapeptide-3, lipobelle soyaglycone, xylitylglucoside, anhydroxyxylitol, xylitol, ethylhexylglycerin, squalene, Triticum vulgare germ oil unsaponifiables, ceramide-3, ethylhexyl stearate, biosaccharide gum-1, paraffinum liquidum, isopropyl palminate, glycerin stearate, D-panthenol, lactic acid, tocopherol and tocopherol derivatives, cetearyl alcohol, dicaprylyl carbonate, butylene alcohol, butylene glycol, and carnosine, butylene glycol cocoate, propylheptyl caprylate, glycine soja sterols (soybean extracts), decyl oleate, PPG-26-buteth-26, potassium ascorbyl tocopheryl phosphate, guar hydroxypropyltrimonium chloride, methyl gluceth-10, or avocado oil. Skin conditioning agents may be incorporated into this composition at 0.01% to 30% by weight of the total composition.
  • In embodiments, the topical composition may be a rash cream to treat diaper rash and other common rashes. In this embodiment, the topical composition may further comprise a soothing agent such as oxidized corn oil to provide a soothing feeling to the skin.
  • In topical compositions for use on nails or hair, agents with keratolytic effect may be added into the topical composition. Hydrolyzed keratin and/or allantoin with keratolytic effect may be used in these embodiments. Keratolytic agents may be incorporated into this composition at 0.1% to 5% by weight of the total composition.
  • Additional preservatives may be added into the topical composition to extend shelf life and prevent microbial growth. Suitable preservatives may be pentylene glycol, phenoxyethanol, methyl and propylparaben, or ethylhexyl glycerin, or benzyl alcohol. Other preservatives suitable for cosmetic use may also be used. Preservatives may be present in the topical composition at 0.5% to 10% by weight of the total composition.
  • The topical formulation may comprise water, preferably de-ionized water, as the base, and bulking agent in this formulation. Water may comprise about 40% to about 80% by weight of the topical composition. However, in an embodiment wherein the topical composition is a lip balm, the composition comprises no water.
  • Viscosity controlling agents and emulsifiers may be necessary to bind water-phase ingredients and oil-phase ingredients. Suitable emulsifiers for these embodiments may be hydrogenated lecithin, glycerin, sodium gluconate, acrylates, C10-30 alkyl acrylate crosspolymer, sodium carboxymethyl betaglucan, hydrogenated castor oil, polyglyceryl-3 methylglucose distearate, cetearyl alcohol, behenyl alcohol, butylene glycol, propylene glycol, xanthan gum, potassium cetyl phosphate, polyglyceryl-6 distearate jojoba esters, polyglyceryl-3 beewax, cetyl alcohol, PEG-800, laureth-7, C13-14 isoparrafin, polyisobutene, sodium carboxymethyl betaglucan, PEG-200 hydrogenated glyceryl palmate, cellulose gum, PEG-7 glyceryl cocoate, or aluminum starch octenylsuccinate.
  • The topical composition may further comprise a foaming agent as needed. Foaming agents may be quillaia saponaria extract or disodium EDTA (disodium ethylenediaminetetraacetic acid).
  • Fragrance agents in these embodiments may be added to increase the aesthetic appeal of the topical composition. Fragrances may be propylparaben, hydrogenated castor oil, cinnamal, eugenol, coumarin, linalool, α-isomethyl ionone, hydroxyisohexyl 3-cyclohexene carboxaldehyde, butylphenyl methylpropional, or natural fragrance essential oils.
  • The topical composition according to the above embodiments may be formulated to be an anti-aging day cream, anti-aging night cream, hand and nail cream, acne treatment cream or tonic, anti-diaper rash cream, shampoo (regular and anti-dandruff), conditioner, face wash, and body wash.
  • In other embodiments, the topical composition is a lip balm. The topical composition may comprise, apart from CBG hemp oil or CBG cannabis oil at about 1% to 3% by weight of the topical composition, cosmetically suitable waxes, cosmetic oils or butter, flavor, and moisturizing agents. CBG hemp oil or CBG cannabis oil as used in these embodiments may have about 3% to 24% CBG, and 1% to 10% CBD by weight, with other naturally occurring cannabinoids at lower weight percentage.
  • Suitable waxes for use in this embodiment may be bee wax, lanolin, candelilla, soy, or carnauba wax. Other skin conditioning agents may be added to give the composition a softer profile. Suitable skin conditioning agents may be cocoa butter, Ricinus communis (castor) seed oil, olive oil, coconut oil, and avocado oil. Other suitable skin conditioning agents may also be used.
  • Flavoring oils, such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any suitable flavor, may be added into the topical composition according to this embodiment.
  • When the topical composition may be a shampoo, conditioner, a face wash, or body wash, the topical composition may contain, apart from CBG hemp oil or CBG cannabis oil, other ingredients common in shampoo, conditioner, face wash, or body wash. As these are rinse-off products, the concentrations of CBG hemp oil or CBG cannabis oil in these products may be at 0.05% to 1% by weight of the topical rinse-off composition.
  • Suitable surfactants, cleansing agents, additives, antimicrobials, and thickeners in these embodiments may be ammonium chloride, ammonium lauryl sulfate, sodium laureth sulfate, sodium lauryl sulfate, piroctone olamine, sodium lauroamphoacetate, polysorbate 20, polysorbate 80, PEG-150, citric acid, quaternium-15, polyquaternium-10, coco-glucoside, cocamide MEA, methylisothiazolinone, or di-PGG-2 myreth-10 adipate. Piroctone olamine may be used as an antimicrobial agent in shampoo embodiments for anti-dandruff purposes.
  • In other embodiments, the topical composition may be a conditioner. The conditioner according to embodiments may comprise, in addition to CBD hemp oil or CBG cannabis oil, certain humectants; certain reconstructors such as hydrolyzed protein, glossers such as silicones; thermal protectors; certain lubricants such as fatty alcohols, panthenol, or dimethicone; certain sequestrants, such as sodium gluconate, potassium gluconate, or calcium disodium ethylene diamine tetra-acetate; antistatic agents; or preservatives.
  • In other embodiments, the topical composition may be a deodorant spray. The deodorant spray according to these embodiments may comprise CBG hemp oil or CBG cannabis oil at 0.1% to 1.5% by weight of the deodorant spray as a whole. CBG hemp oil or CBG cannabis oil as used in these embodiments may have about 3% to 24% CBG, and 1% to 10% CBD by weight, with other naturally occurring cannabinoids at lower weight percentage. The deodorant spray may further comprise alcohol, such as ethanol and isopropyl alcohol as the main carrier. Suitable emulsifiers and humectants may be added, such as glycerin, polysorbate 20, methylcyclodextrin, or ethylhexyl glycerin. Other suitable emulsifiers may also be used. Fragrance in the form of natural essential oils may be added to give a pleasant scent.
  • Flavoring oils, such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any suitable flavor, may be added into the deodorant spray as fragrance according to these embodiments.
  • To make the topical composition, ingredients may be obtained according to the embodiments above. Water phase ingredients may be combined and mixed. Oily phase ingredients may be combined and mixed with heat application at about 50° C. to about 70° C. to reduce viscosity and facilitate mixing. Water phase and oil phase may be combined under continuous mixing and heating.
  • The water phase comprises of de-ionized water, bulking agents, cosmetic fillers, emulsifiers, preservatives, and anti-caking agents. Ingredients for the water phase may be combined and mixed. Water phase ingredients may be separated into different sequences as needed.
  • The oily phase may comprise hemp oil, tocopherol, lipobelle soyaglycone, fragrance, essential oils, and other oily ingredients. Ingredients for the oily phase may be combined and mixed while heated. Other ingredients may be added in sufficient quantities, such as sodium hydroxide for pH balancing purposes.
  • To make the lip balm composition according to embodiments, ingredients may be obtained according to the above embodiments. In one container, combine waxes and heat to about 50° C. to about 70° C. In another container, combine skin conditioning oils and hemp oil with CBD and CBG, then heat to about 35° C. to about 45° C. Combine the oil with the wax; then add flavors as desired. Mix well, pour the hot liquid into molds, then cool down to room temperature. The lip balm composition may be applied to lips.
  • To make the deodorant spray according to embodiments, ingredients may be obtained according to the description above. A base comprising of water and alcohols may be pre-mixed in a container. Emulsifiers and humectants may be mixed with CBG hemp oil or CBG cannabis oil; then added into the base. Fragrance may be added as needed to the composition.
  • Anti-aging creams according to embodiments may be applied at least once daily to human skin to reduce signs of aging, including sagging skin, discoloration, dryness, and crow's feet. Hand and nail cream may be applied at least once daily to nourish and moisturize the skin. Acne cream according to the present invention may be applied at least once daily to prevent and treat acne. Lip balm according to these embodiments may be applied as needed to the lips to moisturize and preserve lips' health.
  • Shampoo, conditioner, face wash, and body wash according to these embodiments may be applied to the hair or skin with water to wash, nourish, and moisturize the hair and the skin. Shampoo, conditioner, face wash, and body wash may be applied daily, or as needed. Deodorant spray may be applied to the skin twice daily or as needed.
    • EXAMPLES Example 1
  • Anti-Aging Day Cream with SPF 15
  • Percentage
    Sequence Ingredient by INCI Name (wt/wt)
    1 De-ionized water 47.750
    1 Disodium EDTA 0.100
    2 Acrylate/C10-30 alkyl acrylate copolymer 0.200
    1 Xanthan gum 0.200
    1 Glycerin 3.000
    1 Potassium Cetyl Phosphate 0.300
    1 Water 8.000
    Polyglyceryl-6 Distearate Jojoba Esters
    1 Polyglyceryl-3 Beeswax, Cetyl Alcohol 6.000
    1 Cetearyl Alcohol 1.500
    2 Ethylhexyl Methoxycinnamate 7.000
    2 Octocrylene 2.000
    1 D-Pantenol 0.500
    2 Tocopherol 0.500
    2 Hemp oil (CBD/CBG) 3.000
    2 Butyl Methoxydibenzoylmethane 3.000
    2 Lipobelle soyaglycone 2.000
    2 Coco-Caprylate 3.000
    2 Butylene Glycol Cocoate 3.000
    2 Prophylheptyl Caprylate 4.000
    1 Preservative 1.000
    3 Water, Sodium Hydroxide 0.450
    Aluminum Starch
    1 Octenylsuccinate 3.000
    2 Fragrance 0.500
    Total 100.00
  • Formulation procedure:
      • 1. In a beaker, combine Sequence #1 ingredients, mix and set aside.
      • 2. In another beaker, combine Sequence #2 ingredients, mix while heat to 50° C. for at least 15 minutes.
      • 3. Heat the beaker with Sequence #1 to 60° C., add Sequence #2 to Sequence #1, continue to mix and heat until the beaker reaches 60° C. Continue to mix for another 10 minutes.
      • 4. Cool the beaker content down to room temperature.
      • 5. Adjust the batch to pH 6.8-8 with Sequence #3.
    Example 2
  • Anti-Aging Night Cream
  • Percentage
    Sequence Ingredient by INCI Name (wt/wt)
    1 De-ionized Water 63.2700
    2 Butyrospermum Parkii 6.3500
    2 Butylene Glycol Dicaprylate/dicaprate 5.0000
    1 Hydrogenated Lecithin 4.5000
    1 Glycerin 3.1875
    1 Betaine 3.0000
    2 Pentylene Glycol 2.2500
    1 Xylitylglucoside 1.5000
    1 Anhydroxyxylitol 0.9000
    2 Fragrance 0.7500
    2 Lupinus Albas Seed Oil 0.7000
    1 Xylitol 0.6000
    2 Phenoxyethanol 0.5175
    1 Sodium Gluconate 0.5000
    1 Ethylhexylglycerin 0.5000
    2 Squalene 0.4500
    2 Hemp oil (CBD/CBG) 2.0000
    1 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.3000
    2 Lipobelle soyaglycone 3.0000
    2 Triticum Vulgare (Wheat) 0.3000
    Germ Oil Unsaponifiables
    1 Alkyl Methacrylates Crosspolymer 0.2100
    3 Potassium Hydroxide 0.1000
    1 Sodium Carboxymethyl Betaglucan 0.0700
    1 Imidazolidinyl Urea 0.0175
    1 Sodium Chloride 0.0165
    2 Ceramide 3 0.0045
    1 Acetyl Hexapeptide-3 0.0025
    Total 100.00
  • Formulation procedure:
      • 1. In a beaker, combine Sequence #1 ingredients, mix and set aside.
      • 2. In another beaker, combine Sequence #2 ingredients, mix while heat to 50° C. for at least 15 minutes.
      • 3. Heat the beaker with Sequence #1 to 60° C., add Sequence #2 to Sequence #1, continue to mix and heat until the beaker reaches 60° C. Continue to mix for another 10 minutes.
      • 4. Cool the beaker content down to room temperature.
      • 5. Adjust the batch to pH 6.8-8 with Sequence #3.
    Example 3
  • Lip Balm
  • Percentage
    Sequence Ingredient by INCI Name (wt/wt)
    2 Cocoa Butter 25.00
    1 Beeswax 21.00
    1 Lanolin 18.00
    1 Carnauba wax 22.00
    2 Avocado oil 5.00
    2 Hemp oil (CBD/CBD) 2.00
    3 Flavor 6.00
    2 Tocopherol 1.00
    Total 100.00
  • Formulation procedure:
      • 1. Combine Sequence #1 in the main beaker, heat to 65° C. and mix. Cool sequence #1 to around 35° C.
      • 2. In another beaker, combine Sequence #2, heat to 40° C. and mix. Pour Sequence #2 into Sequence #1.
      • 3. Add Sequence #3 into the main beaker and mix. Pour the mix into cylindrical molds. Cool the mixture down to room temperature.
    Example 4
  • Eye Cream
  • Percentage
    Sequence Ingredient by INCI name (wt/wt)
    1 De-ionized Water 59.8800
    2 Cetearyl Alcohol 7.5000
    2 Butylene Glycol Dicaprylate/dicaprate 5.0000
    2 Dicaprylyl Carbonate 6.0000
    1 Betaine 3.0000
    1 Cyathea Cumingii Leaf Extract 3.0000
    1 Glycerin 2.0000
    2 Behenyl Alcohol 1.8000
    2 Glyceryl Stearate 1.4000
    2 Butylene Glycol 1.0000
    1 Lecithin 0.9600
    1 Phenoxyethanol 0.5000
    2 Ethylhexylglycerin 0.5000
    2 Fragrance 0.6000
    1 Sodium Gluconate 0.2500
    1 Carnosine 1.0000
    2 Propylene Glycol 0.0500
    2 Glycine Soja (Soybean) Sterols 1.0000
    1 Lactic Acid 0.0280
    1 Butylphenyl Methylpropional 0.0280
    1 Kigelia Africana Extract 0.0500
    3 Quillaia Saponaria Extract 0.0500
    2 Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde 0.0200
    2 Hemp oil (CBD/CBG) 2.0000
    2 Coumarin 0.0180
    2 Linalool 0.0103
    2 Alpha-Isomethyl Ionone 0.0056
    2 Lipobelle soyaglycone 2.0000
    2 Tocopherol 0.1000
    2 Eugenol 0.1000
    2 Cinnamal 0.0500
    1 Silybum Marianum/Silybum Marianum Fruit 0.1000
    Extract
    Total 100.00
    • Example 5
  • Hand and Nail Cream
  • Percentage
    Sequence Ingredient by INCI Name (wt)/wt)
    1 Aqua 56.42
    1 Ethylhexyl Stearate 4.00
    1 Ethylhexyl Methoxycinnamate 5.00
    1 Polyglyceryl-3 Methylglucose Distearate 5.00
    2 Dicaprylyl Carbonate 4.00
    1 Glycerin 6.00
    1 Biosaccharide Gum-1 2.00
    2 Paraffinum Liquidum 4.00
    2 Isopropyl Palmitate 2.00
    2 Glyceryl Stearate 3.00
    2 Hemp oil (CBD/CBG) 2.00
    1 Cetearyl Alcohol 2.00
    1 Vitis Vinifera 1.00
    1 D-Panthenol 1.00
    2 Fragrance 0.60
    1 Hydrolyzed Keratin 0.50
    1 Phenoxyethanol 0.12
    2 Allantoin 0.50
    2 Methylparaben 0.10
    1 Lactic Acid 0.08
    2 PEG-40 Hydrogenated Castor Oil 0.10
    1 Propylparaben 0.05
    1 Ethylhexyl glycerin 0.03
    2 Tocopherol 0.50
    Total 100.00
  • Total 100.00
  • Formulation procedure:
      • 1. In a beaker, combine Sequence #1 ingredients, mix and set aside.
      • 2. In another beaker, combine Sequence #2 ingredients, mix while heat to 50° C. for at least 15 minutes.
      • 3. Heat the beaker with Sequence #1 to 60° C., add Sequence #2 to Sequence #1, continue to mix and heat until the beaker reaches 60° C. Continue to mix for another 10 minutes.
      • 4. Cool the beaker content down to room temperature.
  • The following examples are provided as examples of some embodiments of this invention, without limiting the invention in anyway.
    • Example 6
  • Diaper Rash Cream
  • Ingredient by INCI Name Percentage
    De-ionized 68.50
    Polyglyceryl-3 Methylglucose Distearate 5.00
    Ethylhexyl Stearate 3.00
    Glycerin 5.00
    Cetyl Alcohol 4.00
    Oxidized Corn Oil 4.00
    Butylene Glycol Dicaprylate/dicaprate 4.00
    Hemp oil (CBD/CBG) 1.00
    Decyl Oleate 2.00
    Phenoxyethanol 0.50
    Ethylhexylglycerin 0.50
    Polyacrylamide 1.00
    Fragrance 0.60
    C13-14 Isoparrafin 0.40
    Allantoin 0.30
    Laureth-7 0.10
    Lactic Acid 0.10
    Total 100.00
    • Example 7
  • Anti-Acne Tonic
  • Ingredient by INCI Name Percentage
    De-ionized Water 55.40
    Alcohol 31.00
    Sucrose Laurate 1.50
    Diglyceryn 2.00
    Glucose 2.00
    Methyl Gluceth-10 1.50
    Glyceryl Caprylate 1.50
    PPG-26-Buteth-26 1.00
    Hemp oil (CBD/CBG) 1.00
    Panthenol 0.70
    Phenoxyethanol 0.50
    Ethylhexyl glycerin 0.50
    Isopropyl Alcohol 0.50
    Fragrance 0.50
    Allantoin 0.20
    Potassium Ascorbyl Tocopheryl Phosphate 0.10
    Lactic Acid 0.10
    Total 100.00
    • Example 8
  • Anti-Acne Cream
  • Ingredient by INCI Name Percentage
    De-ionized Water 58.800
    Cetearyl Alcohol 8.000
    Dicaprylyl Carbonate 7.000
    Glycerin 6.000
    Butylene Glycol Dicaprylate/dicaprate 4.000
    Oxidized corn oil 2.000
    Caprylic/Capric Triglyceride 2.500
    Polyacrylate 13 2.000
    Glyceryl Caprylate 1.000
    Cetearyl Glucoside 0.900
    Polyisobutene 1.000
    Hemp oil (CBD/CBD) 2.000
    Sodium Gluconate 1.000
    Fragrance 0.600
    Polysorbate 20 0.200
    Sodium Hydroxide 0.200
    Sodium Chloride 0.100
    Allantoin 0.500
    Oleic Triglyceride 0.200
    Sodium Stearoyl Lactylate 0.100
    Tocopheryl Acetate 0.500
    Sodium Lactate 0.100
    Cetyl Alcohol 0.100
    Sodium Carboxymethyl Betaglucan 0.100
    Phytosterol 0.100
    Carnosine 0.002
    Phenoxyethanol 0.500
    Ethylhexyl glycerin 0.500
    Citric Acid 0.002
    Total 100.0
    • Example 9
  • Face Wash Formulation
  • Ingredient by INCI Name Percentage
    De-ionized Water 51.10
    Alcohol 10.00
    Glycerin 12.00
    Cocamidopropyl Betaine 10.00
    Decyl Glucoside 6.00
    PEG-200 Hydrogenated Glyceryl Palmate 3.00
    PEG-7 Glyceryl Cocoate 2.00
    Methyl Gluceth-10 2.00
    Acrylates/C10-30 Alkyl Acrylate 2.00
    Crosspolymer
    Cellulose Gum 0.50
    Potassium Hydroxide 0.20
    Hemp oil (CBD/CBG) 0.20
    Phenoxyethanol 0.50
    Ethylhexyl glycerin 0.50
    Total 100.00
    • Example 10
  • Body Wash Formulation
  • Ingredient by INCI Name Percentage
    De-ionized Water 70.04
    Sodium Laureth Sulfate 6.00
    Glycerin 3.50
    Cocamidopropyl Betaine 10.00
    Coco-Glucoside 2.00
    Glyceryl Oleate 2.00
    Sodium Chloride 1.00
    Propylene Glycol 1.00
    Fragrance 1.00
    Glycol Distearate 1.00
    Ammonium Lauryl Sulfate 0.50
    Cocamide MEA 0.20
    Laureth-10 0.20
    Guar Hydroxypropyltrimonium Chloride 0.10
    PEG-200 Hydrogenated Glyceryl Palmate 0.10
    Sodium Hydroxide 0.05
    PEG-7 Glyceryl Cocoate 0.10
    Lactic Acid 0.01
    Hemp oil (CBD/CBG) 0.20
    Phenoxyethanol 0.50
    Ethylhexyl glycerin 0.50
    Total 100.00
    • Example 11
  • Anti-Dandruff Shampoo
  • Ingredient by INCI Name Percentage
    De-ionized Water 49.92
    Glycerin 15.00
    Cocamidopropyl Betaine 20.00
    Methyl Gluceth-10 4.00
    Sodium Chloride 2.00
    PEG-800 3.00
    Hemp oil (CBD/CBG) 0.20
    Glyceryl Oleate 1.00
    Piroctone olamine 0.30
    Panthenol 1.00
    Coco-Glucoside 1.00
    Cellulose Gum 0.40
    Sodium Gluconate 0.50
    Fragrance 0.60
    Citric Acid 0.08
    Phenoxyethanol 0.50
    Ethylhexyl glycerin 0.50
    Total 100.00
    • Example 12
  • Deodorant Spray
  • Ingredient by INCI Name Percentage
    Ethanol 72.50
    De-ionized Water 14.00
    Glycerin 6.00
    Isopropyl Alcohol 3.00
    Fragrance 3.00
    Ethylhexylglycerin 1.00
    Hemp oil (CBD/CBG) 0.50
    Total 100.00
  • All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
  • It will be readily apparent to those skilled in the art that a number of modifications and changes may be made without departing from the spirit and the scope of the present invention. It is to be understood that any ranges, ratios, and range of ratios that can be derived from any of the data disclosed herein represent further embodiments of the present disclosure and are included as part of the disclosure as though they were explicitly set forth. This includes ranges that can be formed that do or do not include a finite upper and/or lower boundary. Accordingly, a person of ordinary skill in the art will appreciate that such values are unambiguously derivative from the data presented herein.

Claims (7)

What is claimed is:
1. A deodorant spray composition comprising:
hemp oil containing cannabigerol at about 3 to 24 by weight percent and cannabidiol at about 1 to 10 by weight percent;
at least one alcohol;
at least one emulsifier;
water; and
fragrance.
2. The deodorant spray of claim 1, wherein the hemp oil comprises about 0.1% to about 1.5% of the deodorant spray composition by weight.
3. The deodorant spray of claim 1, wherein the at least one alcohol is ethanol.
4. The deodorant spray of claim 1, wherein the at least one alcohol isopropyl alcohol.
5. The deodorant spray of claim 1, wherein the at least one alcohol is a mixture of ethanol and isopropyl alcohol.
6. The deodorant spray of claim 1, wherein the at least one emulsifier is at least one of glycerin, polysorbate 20, methylcyclodextrin, or ethylhexyl glycerin.
7. The deodorant spray of claim 1, wherein the fragrance is at least one of apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, or honey.
US16/784,086 2015-02-16 2020-02-06 Cosmetic and topical compositions comprising cannabigerol Abandoned US20200188325A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/784,086 US20200188325A1 (en) 2015-02-16 2020-02-06 Cosmetic and topical compositions comprising cannabigerol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562116905P 2015-02-16 2015-02-16
US15/044,322 US20160235661A1 (en) 2015-02-16 2016-02-16 Cosmetic and topical compositions comprising cannabigerol
US16/784,086 US20200188325A1 (en) 2015-02-16 2020-02-06 Cosmetic and topical compositions comprising cannabigerol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/044,322 Continuation US20160235661A1 (en) 2015-02-16 2016-02-16 Cosmetic and topical compositions comprising cannabigerol

Publications (1)

Publication Number Publication Date
US20200188325A1 true US20200188325A1 (en) 2020-06-18

Family

ID=56620605

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/044,322 Abandoned US20160235661A1 (en) 2015-02-16 2016-02-16 Cosmetic and topical compositions comprising cannabigerol
US16/784,086 Abandoned US20200188325A1 (en) 2015-02-16 2020-02-06 Cosmetic and topical compositions comprising cannabigerol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/044,322 Abandoned US20160235661A1 (en) 2015-02-16 2016-02-16 Cosmetic and topical compositions comprising cannabigerol

Country Status (6)

Country Link
US (2) US20160235661A1 (en)
EP (1) EP3258942B1 (en)
DK (1) DK3258942T3 (en)
ES (1) ES2860452T3 (en)
HK (1) HK1248526A1 (en)
WO (1) WO2016133824A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516120A (en) * 2021-02-05 2021-03-19 云南维他源生物科技有限公司 ASBD composition with anti-aging and anti-inflammatory effects and application thereof
WO2022191551A1 (en) * 2021-03-08 2022-09-15 주식회사 엘지생활건강 Composition comprising cannabigerol

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016208858A1 (en) * 2016-05-23 2017-11-23 Henkel Ag & Co. Kgaa Deodorant combination of active ingredients
WO2018071452A1 (en) 2016-10-11 2018-04-19 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
CN108451799A (en) * 2016-12-09 2018-08-28 汉义生物科技（北京）有限公司 A kind of hand cleanser and preparation method thereof
DE202016107001U1 (en) * 2016-12-15 2018-03-26 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Cosmetic preparation in gel form
US10857107B2 (en) 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
EP3621586A4 (en) * 2017-05-07 2020-12-23 Locus IP Company, LLC Cosmetic compositions for skin health and methods of using same
US10624939B2 (en) * 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US10543164B2 (en) 2017-06-30 2020-01-28 The Procter & Gamble Company Deodorant compositions
US10905647B2 (en) 2017-06-30 2021-02-02 The Procter & Gamble Company Antiperspirant and deodorant compositions
EP3644951A1 (en) 2017-06-30 2020-05-06 The Procter and Gamble Company Hair care compositions comprising a 2-pyridinol-n-oxide material and an iron chelator
WO2019006104A2 (en) 2017-06-30 2019-01-03 The Procter & Gamble Company Deodorant and antiperspirant compositions
BR112020000035B1 (en) 2017-07-06 2023-03-14 Dsm Ip Assets B.V. TOPICAL COMPOSITION COMPRISING ERYTHRULOSE AND GLYCERYL CAPRYLATE, USES OF ERYTHRULOSE AND GLYCERYL CAPRYLATE, AND METHOD OF EXTERMINATION AND/OR GROWTH INHIBITION OF P. ACNES AND C. ALBICANS
CN109248107A (en) * 2017-07-12 2019-01-22 国农兴悦(北京)生态科技有限公司 Skin care oil and preparation method thereof
US11484510B2 (en) * 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
US20190060250A1 (en) * 2017-08-28 2019-02-28 Axim Biotechnologies, Inc. Method to treat psoriasis
US10272051B2 (en) * 2017-08-28 2019-04-30 Axim Biotechnologies, Inc. Method to treat atopic dermatitis
KR102063524B1 (en) * 2017-11-10 2020-01-08 안용훈 Cosmetic composition including Cannabidiol
US20200330364A1 (en) * 2017-11-13 2020-10-22 Smoky Valley Lotions & Soaps Insect repellent compositions and methods of use
US10905730B2 (en) * 2017-11-14 2021-02-02 Agnes V. MOJSA Phytocannabinoid topical compositions for releiving pain
CN107789255A (en) * 2017-11-30 2018-03-13 安徽扬子生物科技有限公司 A kind of Jasmine antibacterial bath cream compound method
US20200405685A1 (en) * 2017-12-08 2020-12-31 Biotech Institute, Llc High cannabigerol cannabis plants, methods of producing and methods of using them
AU2019206685B2 (en) * 2018-01-13 2023-07-13 Truetiva Inc. Anti-aging and skin tone lightening compositions and methods for same
US20190224137A1 (en) * 2018-01-24 2019-07-25 Botanix Pharmaceuticals Ltd. Cannabinoid Dosing Regime for Acne
BR112020014955A2 (en) * 2018-01-24 2020-12-22 Botanix Pharmaceuticals Ltd CANNABINOID DOSAGE REGIME FOR ACNE
BR112020020850A2 (en) 2018-04-09 2021-01-19 Ellevet Sciences HEMP EXTRACT FOR PAIN TREATMENT IN ANIMALS
CN108354865A (en) * 2018-04-17 2018-08-03 五池（珠海）日化科技有限公司 Wrinkle antiallergic composition and preparation method thereof is removed in a kind of moisturizing
CN108524414A (en) * 2018-04-20 2018-09-14 烟台汉麻生物技术有限公司 A kind of more effect Chinese pitted skin films and its preparation process
EP3801463A4 (en) 2018-05-25 2022-05-04 Locus IP Company, LLC Therapeutic compositions for enhanced healing of wounds and scars
WO2019234743A1 (en) * 2018-06-06 2019-12-12 Icdpharma Ltd. Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
AU2019412836A1 (en) * 2018-12-25 2021-07-01 Epm (Ip), Inc. Cannabidiolic acid esters for cosmetic or edible compositions
CN113993517A (en) * 2019-06-18 2022-01-28 博塔尼克斯制药有限公司 Antibacterial dosage regimen using cannabinoids
CA3144503A1 (en) * 2019-06-26 2020-12-30 CannPal Animal Therapeutics Limited Cbd composition
CA3149121A1 (en) 2019-07-29 2021-02-04 Echo Pharmaceuticals B.V. Treatment of inflammatory skin conditions
WO2021050429A1 (en) * 2019-09-10 2021-03-18 Pureform Global, Inc. Topical composition for treatment of pain
MX2022003864A (en) * 2019-10-07 2022-04-18 Colgate Palmolive Co Personal care compositions and methods.
CN110711165A (en) * 2019-11-03 2020-01-21 上海悦目化妆品有限公司 Anti-aging firming beauty cream containing kangaroo paw extract
MX2022005571A (en) * 2019-11-07 2022-06-09 Amyris Inc Compositions and methods for delivering cannabinoids to skin.
US11213467B2 (en) 2019-11-07 2022-01-04 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
US20210169823A1 (en) * 2019-12-10 2021-06-10 Avicanna Inc. Topical skin care composition and methods for treating eczema
BR112022011215A2 (en) * 2019-12-16 2022-08-23 Colgate Palmolive Co COMPOSITIONS FOR PERSONAL CARE AND METHODS FOR THESE
CN111956535A (en) * 2019-12-30 2020-11-20 云南汉盟制药有限公司 Conditioner composition and preparation method and application thereof
WO2021207182A1 (en) * 2020-04-06 2021-10-14 Jupiter Wellness, Inc. Cbd sunscreen formulations and uses thereof
US11524040B2 (en) 2020-08-24 2022-12-13 Charlotte's Web, Inc. Composition for the treatment of acne
WO2022150761A1 (en) * 2021-01-11 2022-07-14 Amyris, Inc. Cosmetic compositions and methods of use thereof
CA3211573A1 (en) * 2021-03-08 2022-09-15 Aras Azadian Topical cannabinoid compositions and methods for treating skin diseases
WO2023012803A1 (en) * 2021-08-05 2023-02-09 Technion Research & Development Foundation Limited Cannabinoids and uses thereof in treatment of a disease
FR3133750A1 (en) * 2022-03-25 2023-09-29 Helioscience New compositions combining hemp derivatives and their use, particularly in cosmetics
US20230310297A1 (en) * 2022-04-01 2023-10-05 TF Holdings LLC Skin treatment composition containing cannabinoids

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805703C2 (en) * 1998-02-06 2001-05-03 Cognis Deutschland Gmbh Hair care products
CN1394135A (en) * 2000-01-10 2003-01-29 西巴特殊化学品控股有限公司 Use of microbially encapsulated materials in cosmetic end formulations
US6361806B1 (en) * 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
GB0229071D0 (en) * 2002-12-13 2003-01-15 Unilever Plc Cosmetic method and composition for enhancing attractiveness
DE10357046A1 (en) * 2003-12-04 2005-06-30 Beiersdorf Ag Cosmetic or dermatological preparations containing a combination of green dye and anti-inflammatory agent
DE102004037753A1 (en) * 2004-08-04 2006-03-16 Henkel Kgaa Skin cosmetic preparation
US20070280898A1 (en) * 2006-06-06 2007-12-06 P & H Enterprises Of Marco Inc. Dermatological compositions
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008079898A1 (en) * 2006-12-20 2008-07-03 Pharmwest, Inc. Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
US20080286390A1 (en) * 2007-05-16 2008-11-20 Judy Tanyi Skin care composition
KR100893106B1 (en) * 2007-07-09 2009-04-10 정정임 Composition for promoting hair growth
EP2192888B1 (en) * 2007-10-02 2016-05-11 Kuhs GmbH Cosmetic or pharmaceutical composition for topical application
US20110250227A1 (en) * 2008-08-11 2011-10-13 Hanan Elraz Composition for treatment of the skin
EP2201942A1 (en) * 2008-12-23 2010-06-30 Intendis GmbH Compound with hemp oil for the treatment of topical illnesses
US8685381B2 (en) * 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
FR2966698B1 (en) * 2010-10-29 2013-04-26 Dermo Cosmetique Animale Lab De ANTI-MICROBIAL DERMO-COSMETIC COMPOSITION FOR ANIMALS
FR2967350B1 (en) * 2010-11-15 2015-05-01 Oreal SOLID COSMETIC COMPOSITION IN THE FORM OF COMPACT POWDER
FR2972923B1 (en) * 2011-03-25 2013-08-23 Urgo Lab FILMOGENIC COMPOSITION CONTAINING A SOLAR FILTER, ITS USE FOR THE TREATMENT OF SCARS
CN104066424A (en) * 2011-09-02 2014-09-24 伯特氏农场有限责任公司 Personal care compositions comprising squash or pumpkin extract
US8722106B2 (en) * 2011-12-02 2014-05-13 The MotherVine Nutraceuticals Co. LLC Lip balm composition
US20130319889A1 (en) * 2012-05-29 2013-12-05 Surgeons Skin Recovery Stick, Llc Skin care and restoration composition and methods
US9597279B2 (en) * 2014-02-28 2017-03-21 HDDC Holdings, LLC Anti-aging dermal composition comprising herbal extracts

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516120A (en) * 2021-02-05 2021-03-19 云南维他源生物科技有限公司 ASBD composition with anti-aging and anti-inflammatory effects and application thereof
WO2022191551A1 (en) * 2021-03-08 2022-09-15 주식회사 엘지생활건강 Composition comprising cannabigerol

Also Published As

Publication number Publication date
EP3258942A1 (en) 2017-12-27
HK1248526A1 (en) 2018-10-19
WO2016133824A1 (en) 2016-08-25
US20160235661A1 (en) 2016-08-18
EP3258942B1 (en) 2021-01-13
ES2860452T3 (en) 2021-10-05
EP3258942A4 (en) 2018-11-14
DK3258942T3 (en) 2021-01-25

Similar Documents

Publication Publication Date Title
EP3258942B1 (en) Cosmetic and topical compositions comprising cannabigerol and cannabidiol
Pundir et al. Ethnomedicinal uses, phytochemistry and dermatological effects of Hippophae rhamnoides L.: A review
KR20190128666A (en) Kit of Cosmetic Skincare Compositions
JP7275103B2 (en) Novel cosmetic use of Nephelium lapaceum extract
US20160235794A1 (en) Lipid extract of passiflora seeds
CA2895218A1 (en) Extract of passionflower seeds and cosmetic, pharmaceutical, dermatological and nutraceutical compositions comprising same
KR20050071464A (en) Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto
KR102142311B1 (en) Skin external composition comprising tangeretin
EP2691074A1 (en) Composition based on camellia japonica and polygonum hydropiper for protecting the skin
JP2021509413A (en) Kapok tree flower extract and cosmetological, pharmaceutical or dermatological compositions containing it
Pinto et al. Cosmetics—Food waste recovery
KR20160120355A (en) Skin-brightening cosmetic composition
KR20190128665A (en) Beauty skincare composition
EP2100593B1 (en) Ternary mixtures with increased collagen synthesis
TWI523666B (en) Compositions comprising lilium martagon extracts and uses thereof
KR101744889B1 (en) Composition for Anti-oxidation, Whitening and Wrinkles protection
KR101921043B1 (en) Compositions comprising lilium martagon extracts and uses thereof
CN110072516B (en) Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients
JP2002308750A (en) Skin care preparation
KR101304677B1 (en) A chestnut bur extracts and a cosmetic composition containing the chestnut bur extracts as an active ingredient
KR102525579B1 (en) Composition for protecting skin comprising extract of Oryza Sativa(Rice), Phragmites Communis, Zea Mays(Corn) Silk, Malva Sylvestris(Mallow) and Aloe Barbadensis as active ingredient
Sang et al. Natural alternatives from your garden for hair care: Revisiting the benefits of tropical herbs
KR20170137559A (en) Composition for improving skin condition comprising herb extracts mixture
KR102397926B1 (en) Composition for improving skin
ES2961288T3 (en) Cosmetic use of plant extracts

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: APIRX PHARMACEUTICAL USA, LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AXIM BIOTECHNOLOGIES, INC.;REEL/FRAME:052752/0519

Effective date: 20200521

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION